Netherlands· NL-6df0b96fd5d1

Bleomedac, poeder voor oplossing voor injectie 15000 IU (Ph. Eur.)

A bleomycin product containing bleomycinesulfaat + bleomycinesulfaat, registered in Netherlands by Medac Gesellschaft für klinische Spezialpräparate mbH. The same ATC class is registered in 15 of our 19 countries.

ATC L01DC01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about bleomycinesulfaat + bleomycinesulfaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Bleomycin is registered in 15 of 19 countries.

Countries holding a registration under ATC L01DC01 (bleomycin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search bleomycin products by name

Bleomycin · ATC L01DC01

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: BLEOMYCINESULFAAT + BLEOMYCINESULFAAT
Manufacturer: Medac Gesellschaft für klinische Spezialpräparate mbH
Country: Netherlands (NL)
ATC code: L01DC01
ATC class: Bleomycin
Defined daily dose: 3 mg, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
105676

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

212 interactions on record for bleomycin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check bleomycin against other medicines How interaction checks work

Bleomycin · interactions on record

212 records

33 severe
105 moderate
15 minor
59 info

Most severe, free to view

CladribineL01BB04severe
Brentuximab vedotinL01FX05severe
Brentuximab vedotinL01XC12severe
Talimogene laherparepvecL01XL02severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bleomycin in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bleomycin products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

Austria · Bleomycin Accord, Bleomycin Baxter
Belgium · Bleomycine Accord
Czechia · Bleomycin Accord
Germany · Bleo-Cell, Bleomycin Accord
Denmark · Bleomycin Accord, Bleomycin Baxter
Spain · Bleomicina Accord, Bleomicina Viatris
Finland · Bleomycin Accord
France · Bleomycine Accord
United Kingdom (Northern Ireland) · Bleomycin, Bleomycin Accord Healthcare
Iceland · Bleomycin Baxter
Norway · Bleomycin Accord, Bleomycin Baxter
Poland · Bleomedac, Bleomycyna
Portugal · Bleomicina Accord
Romania · Bleomicină Accord
Sweden · Bleomycin Accord, Bleomycin Baxter

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/b4121541-47e0-452c-af72-0f7653fa985d
GET /v1/drugs/b4121541-47e0-452c-af72-0f7653fa985d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor oplossing voor injectie",
  "route": "Intramusculair gebruik, Subcutaan gebruik, Intraveneus gebruik, Intra-arterieel gebruik, Intrapleuraal gebruik, Intratumoraal gebruik, Intraperitoneaal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h105676_smpc.pdf",
  "strength": null,
  "atc_label": "Bleomycin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg105676",
  "excipients": [
    "GEEN HULPSTOFFEN",
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "BLEOMYCINESULFAAT",
    "BLEOMYCINESULFAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h105676.pdf",
  "authorised_at": "2011/01/17",
  "procedure_number": "NL/H/1792/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "105676",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about bleomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console